Jarushka Naidoo: Phase II Lazertinib in EGFR+ NSCLC with CNS disease
Jarushka Naidoo shared a post on X:
“Phase II Lazertinib in EGFR+ NSCLC with CNS disease, after 1st/2nd generation TKIs, JAMA Oncology:
– 38 patients 12 with LMD
– iORR 55%, iPFS 15.8m
– csf penetration rate 46.2%
Unclear what this adds in the context of osi, but appears an effective option.”
Source: Jarushka Naidoo/X
Authors: Min Hee Hong, Yoon Ji Choi, Hee Kyung Ahn, Sun Min Lim, Bhumsuk Keam, Dong-Wan Kim, Tae Min Kim, Jeonghwan Youk, Yu Jung Kim, Shinwon Hwang, Sangwoo Kim, Ju Won Kim, Hye Ryun Kim, and Jin Hyoung Kang.
Dr. Jarushka Naidoo is a thoracic oncologist at the Beaumont Hospital Dublin (Ireland), Professor in RCSI and Adjunct Professor of Oncology at Johns Hopkins University. She currently serves as national lung cancer lead for Cancer Trials Ireland. She serves on several international guideline panels including ASCO and SITC (Society of Immunotherapy for Cancer), and is an experienced clinical trialist- having developed and completed several investigator-initiated, industry-funded and cooperative group clinical trials. She has received a number of grants including a young investigator award from the International Association for the Study of Lung Cancer (IASLC), Lung Cancer Foundation of America (LCFA), and a career development award from the National Institutes of Health (NIH) KL2-program. She is the IASLC Communications Committee Chair.